References
- Jain S, Williams DJ, Arnold SR, et al. Community-acquired pneumonia
requiring hospitalization among U.S. children. N Engl J Med,2015 ; 372(9): 835-845.
- Komatsu H, Tsunoda T, Inui A, Sogo T, Fujisawa T. Characteristics of
hospitalized children infected with macrolide-resistant Mycoplasma
pneumonia. Braz J Infect Dis, 2014 ; 18(3): 294-299.
- Izumikawa K. Clinical Features of Severe or Fatal Mycoplasma
pneumoniae Pneumonia.Front Microbiol, 2016 ; 7: 800
- Yan C, Sun HM, Zhao HQ. Latest surveillance data on Mycoplasma
pneumoniae infections in children, suggesting a new epidemic occurring
in Beijing. J Clin Microbiol, 2016 ; 54: 1400-1401.
- Lee KY, Lee HS, Hong JH, et al . Role of prednisolone treatment
in severe Mycoplasma pneumoniae pneumonia in children. Pediatr
Pulmonol, 2006 ; 41: 263-268.
- Li CC, Shang YX, Shen XZ, Chen ZM, Zhao XY. Guidelines for the
management of community acquired pneumonia in children (revised in
2013).Chinese Journal of Pediatrics, 2013 ; (10): 745-752.
- Bajantri B, Venkatram S, Diaz-Fuentes G.
Mycoplasma pneumoniae: a
potentially severe infection. J Clin Med Res, 2018 ; 10:
535-544.
- Yan C, Xue GH, Zhao HQ, et al . Molecular and clinical
characteristics of severe Mycoplasma pneumoniae pneumonia in
children.Pediatr Pulmonol, 2019 ; 54(7): 1012-1021.
- Chan ED, Welsh CH. Fulminant Mycoplasma pneumoniae pneumonia.West J
Med, 1995 ; 162(2): 133-142.
- Colom AJ, Teper AM. Post-infectious bronchiolitis obliterans.Pediatr
Pulmonol, 2019 ; 54(2): 212-219
- Moonnumakal SP, Fan LL. Bronchiolitis obliterans in children.Curr Opin
Pediatr, 2008 ; 20(3): 272-278.Table 1: General informations